Compared with women whose blood pressure during pregnancy was normal, women with a history of hypertensive disorders of pregnancy, such as preeclampsia.
Updated WIC in Pregnancy Boosts Infant Outcomes medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Related Company:
Vermont Business Magazine In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support such as the need for ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world. Dr Mary Cushman, at the University of Vermont s Larner College of Medicine, is a lead investigator on one aspect of the trial. The trial does not include any Vermont patients.
E-Mail
(Boston) Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs in the lungs. This condition occurs when that lung tissue becomes thick and stiff for unknown reasons. Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that make it progressively more difficult to breathe.
Treatments often are ineffective and the development of novel therapeutics is hampered due to lack of available human in vitro models that are needed to understand pathogenesis or develop novel drug therapies.
In response, a team of researchers led by Darrell Kotton, MD, the David C. Seldin Professor of Medicine at Boston University School of Medicine (BUSM), has been awarded a four-year, $2.4 million U01 grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to better understand the mechanisms that initiate and perpetuate this deadly disease.
BU researchers awarded $2.4 million NIH grant to study idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a serious chronic disease that affects the tissue surrounding the air sacs in the lungs. This condition occurs when that lung tissue becomes thick and stiff for unknown reasons. Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that make it progressively more difficult to breathe.
Treatments often are ineffective and the development of novel therapeutics is hampered due to lack of available human in vitro models that are needed to understand pathogenesis or develop novel drug therapies.
In response, a team of researchers led by Darrell Kotton, MD, the David C. Seldin Professor of Medicine at Boston University School of Medicine (BUSM), has been awarded a four-year, $2.4 million U01 grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to better understand the mechanisms that initiate and perp